HUTCHMED ANNOUNCES CHINA NMPA APPROVAL OF SYVIK® (SOVLEPLENIB) FOR THE TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA AND WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA

Reuters · 2d ago

Please log in to view news